The estimated Net Worth of Jeffrey Alan Wolf is at least 1.19 百万$ dollars as of 1 April 2015. Mr Wolf owns over 10,842 units of Heat Biologics Inc stock worth over 25,804$ and over the last 12 years he sold HTBX stock worth over 0$. In addition, he makes 1,160,609$ as Founder、 Chairman、 CEO & Pres at Heat Biologics Inc.
Mr has made over 1 trades of the Heat Biologics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 10,842 units of HTBX stock worth 976$ on 1 April 2015.
The largest trade he's ever made was exercising 10,842 units of Heat Biologics Inc stock on 1 April 2015 worth over 976$. On average, Mr trades about 434 units every 0 days since 2013. As of 1 April 2015 he still owns at least 10,842 units of Heat Biologics Inc stock.
You can see the complete history of Mr Wolf stock trades at the bottom of the page.
Jeffrey Alan Wolf is the Founder, Chairman, CEO & Pres at Heat Biologics Inc.
As the Founder、 Chairman、 CEO & Pres of Heat Biologics Inc, the total compensation of Mr Wolf at Heat Biologics Inc is 1,160,609$. There are no executives at Heat Biologics Inc getting paid more.
Mr Wolf is 57, he's been the Founder、 Chairman、 CEO & Pres of Heat Biologics Inc since . There are 3 older and 1 younger executives at Heat Biologics Inc. The oldest executive at Heat Biologics Inc is Dr. Anthony M. Manning Ph.D., 59, who is the Chief Scientific Advisor.
Jeffrey's mailing address filed with the SEC is C/O HEAT BIOLOGICS, INC., 627 DAVIS DRIVE, MORRISVILLE, NC, 27560.
Over the last 11 years, insiders at Heat Biologics Inc have traded over 311,853$ worth of Heat Biologics Inc stock and bought 1,805,692 units worth 1,373,576$ . The most active insiders traders include Louis C Bock、Michael Kharitonov、John K A Prendergast. On average, Heat Biologics Inc executives and independent directors trade stock every 319 days with the average trade being worth of 582,988$. The most recent stock trade was executed by John K A Prendergast on 14 May 2021, trading 35,000 units of HTBX stock currently worth 205,450$.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
Heat Biologics Inc executives and other stock owners filed with the SEC include: